AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our focus is on cardiac surgery-associated renal damage (CSA-RD), which occurrs in 40% of all cardiac surgeries. Our proprietary compound, ilofotase alfa, has a demonstrated safety profile and showed reno-protective effects in global clinical trials involving over 1,000 subjects. In addition, based on preclinical data showing improved overall survival and restored phenotypes associated with hypophosphatasia (HPP), as well as a biomarker dose response in adult patients with HPP treated with ilofotase alfa, we are developing ilofotase alfa as a potential enzyme replacement therapy in HPP. We are a dedicated team driven to bring treatment options to severely ill patients, their families and health care professionals.